PIK3CA and neoplasm: Prior to administration of HER2-targeted therapies, in 28.6% of the patients, HER2-amplified CTCs had PIK3CA mutations, known to be associated with resistance to anti-HER2 treatment and worse outcome of patients with HER2-positive tumours [111,147,148].